KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Inventory (2016 - 2024)

Historic Change in Inventory for Nektar Therapeutics (NKTR) over the last 15 years, with Q4 2024 value amounting to -$1.3 million.

  • Nektar Therapeutics' Change in Inventory fell 2184.87% to -$1.3 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 39619.77%. This contributed to the annual value of -$497000.0 for FY2024, which is 2889.84% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Change in Inventory of -$1.3 million as of Q4 2024, which was down 2184.87% from -$123000.0 recorded in Q3 2024.
  • In the past 5 years, Nektar Therapeutics' Change in Inventory registered a high of $2.4 million during Q4 2020, and its lowest value of -$2.4 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Inventory was $389500.0 (2020), whereas its average is $267050.0.
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Change in Inventory showed a top increase of 57037.91% in 2023 and a maximum decrease of 83862.07% in 2023.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Change in Inventory stood at $2.4 million in 2020, then crashed by 80.38% to $471000.0 in 2021, then plummeted by 69.21% to $145000.0 in 2022, then crashed by 838.62% to -$1.1 million in 2023, then decreased by 21.85% to -$1.3 million in 2024.
  • Its Change in Inventory was -$1.3 million in Q4 2024, compared to -$123000.0 in Q3 2024 and -$212000.0 in Q2 2024.